Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Crystal Growth & Design called Controlling the Synthesis of Metal-Organic Framework UiO-67 by Tuning Its Kinetic Driving Force, Author is Kaur, Gurpreet; Oeien-Oedegaard, Sigurd; Lazzarini, Andrea; Chavan, Sachin Maruti; Bordiga, Silvia; Lillerud, Karl Petter; Olsbye, Unni, which mentions a compound: 1762-34-1, SMILESS is CC1=CN=C(C=C1)C1=NC=C(C)C=C1, Molecular C12H12N2, SDS of cas: 1762-34-1.
The successful synthesis of metal-organic framework (MOF) compounds relies on an intricate interplay between the components of the synthesis liquor at the given synthesis conditions. The interdependence of modulator, linker, and solvent amounts in the synthesis of the Zr-based MOF, UiO-67, is explored. Probably control of linker vacancy defects in UiO-67 is feasible by tuning the ratios of these components, and such control derives from recognizing the kinetic driving forces during MOF crystal growth. Linker vacancy defects (and modulator mols. occupying linker sites) can be reduced by limiting the solvent amount to maintain a saturated concentration of linker throughout the synthesis. The method enables formation of UiO-67 with an ideal 1:1 ratio between Zr and the 4,4′-biphenyldicarboxylic acid linker, without surplus linker in the mother liquor or addnl. post-synthetic steps, and reduces the amount of DMF solvent to <20% the amount in previously reported procedures. When you point to this article, it is believed that you are also very interested in this compound(1762-34-1)SDS of cas: 1762-34-1 and due to space limitations, I can only present the most important information.